

## PRESS RELEASE

Of interest to editors and journalists covering:  
Biotech, Medical Research, Pharmaceuticals, Public Companies, TX Business News

Health Discovery Corporation Announces Agreement With M.D. Anderson Cancer  
Center for Biomarker and Pathway Discovery in Prostate Cancer

WACO, Texas - Jan. 26, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY) today announced the signing of its second Biomarker and Pathway Discovery Agreement with The University of Texas, M.D. Anderson Cancer Center in Houston Texas. Under the terms of the Agreement, The University of Texas, M.D. Anderson Cancer Center, has granted the Company a first option to obtain an exclusive worldwide royalty-bearing commercial license to commercialize any discovered prostate cancer biomarkers or pathways identified by the Company utilizing its proprietary and patent protected Fractal Genomics Modeling (FGM) techniques.

For the third time in four years, The University of Texas M.D. Anderson Cancer Center is ranked the nation's top cancer hospital in U.S. News and World Report's "America's Best Hospitals" survey, published in the magazine's July 28 2003 issue.

Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of Health Discovery Corporation stated, "We are honored that our Company was again selected by the Physicians and Clinical Scientists at M.D. Anderson Cancer Center to utilize our unique approach to systems biology to discover new patterns of biomarkers and pathways associated with prostate cancer." Dr. Barnhill continued, "we look forward to working closely with these world renowned experts at M.D. Anderson Cancer Center to analyze, discover, patent protect, and commercialize our findings in the diagnosis and treatment of prostate cancer."

Dr. Herbert Fritsche, Professor and Chief of Clinical Chemistry, at M.D. Anderson Cancer Center said, "This second collaboration with Health Discovery Corporation will give us access to a new systems biology approach for data analysis that will lead to new biomarker and pathway discovery in prostate cancer. We hope to use the findings of this study to develop new diagnostic approaches for prostate cancer and improve the clinical management of these patients."

U.S. Cancer Statistics: 2000 Incidence recently released by the Department of Health and Human Services (HHS) shows that prostate cancer is the leading cancer overall in men in the United States and according to the National Institutes of Health, in 1997, the estimated number of new cases of prostate cancer in the United States alone is 209,900, and the estimated number of deaths from this disease is 41,800.

Health Discovery Corporation is a systems biology oriented biomarker and pathway discovery company, which uses proprietary advanced mathematical platforms, such as Fractal Genomics Modeling (FGM) techniques, to help identify and characterize diagnostic targets and therapeutic candidates. Focusing on disease vs. normal, within complex genomic, proteomic and clinical data sets, Health Discovery Corporation was established to provide pharmaceutical and diagnostic companies with a broad range of analytical and decision support solutions to accelerate effective diagnostic and drug discovery. Founded in September 2003, the Company has offices in Texas, Georgia, and California. For more information contact Robert S. Braswell IV of Health Discovery Corporation +1-866-953-9031 or Info@dwcell.com.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

MEDIA CONTACT:

Robert S. Braswell IV  
Of Health Discovery Corporation  
+1-866-953-9031  
Info@dwcell.com

(OTC BB: HDVY)

# # #

[ source of news = Health Discovery Corporation ]  
ref: [http://www.send2press.com/2archive/2004/pr\\_04\\_0126-hdvy.txt](http://www.send2press.com/2archive/2004/pr_04_0126-hdvy.txt)  
[http://www.send2press.com/2archivePDF/pr\\_04\\_0126-hdvy.pdf](http://www.send2press.com/2archivePDF/pr_04_0126-hdvy.pdf)

-----  
\*IMPORTANT NOTE TO MEDIA:

to reach the organization releasing this news, please contact:  
Info@dwcell.com

If used for publication, please send specimen copy.  
-----

S2PPRN-R/6c/ TX / Waco, Texas / Copr. (c) 2004 Send2Press.

This release was issued on behalf of the above organization by  
Send2Press(tm), a unit of Neotrope(R). <http://www.Send2Press.com> .